Post hoc secondary analysis of the ADORE trial (761 pregnant women): in FADS Indel I-allele carriers, 1,000 mg/d DHA was associated with less early preterm birth than 200 mg/d (1.1% vs 4.3%); in D/D women high dose had little effect but more births at ≥40 weeks.
Secondary analysisn = 761
Li et al. Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial